BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21049561)

  • 41. Optimal staging system for predicting the prognosis of patients with hepatocellular carcinoma in China: a retrospective study.
    Su L; Zhou T; Zhang Z; Zhang X; Zhi X; Li C; Wang Q; Jia C; Shi W; Yue Y; Gao Y; Cheng B
    BMC Cancer; 2016 Jul; 16():424. PubMed ID: 27387757
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
    Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z
    J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt.
    Gomaa AI; Hashim MS; Waked I
    PLoS One; 2014; 9(3):e90929. PubMed ID: 24603710
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Barcelona clinic liver cancer-stage C hepatocellular carcinoma: A novel approach to subclassification and treatment.
    Jun CH; Yoon JH; Cho E; Shin SS; Cho SB; Kim HJ; Park CH; Kim HS; Choi SK; Rew JS
    Medicine (Baltimore); 2017 Apr; 96(17):e6745. PubMed ID: 28445298
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic implication of serum vascular endothelial growth factor in advanced hepatocellular carcinoma staging.
    Yegin EG; Siykhymbayev A; Eren F; Bekiroglu N; Ozdogan OC
    Ann Hepatol; 2013; 12(6):915-25. PubMed ID: 24114822
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients.
    Heinrich S; Sprinzl M; Schmidtmann I; Heil E; Koch S; Czauderna C; Heinrich B; Philippe P Diggs L; Wörns MA; Kloeckner R; Galle PR; Marquardt JU; Weinmann A
    United European Gastroenterol J; 2020 May; 8(4):444-452. PubMed ID: 32213028
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A new staging system for resectable hepatocellular carcinoma: comparison with six existing staging systems in a large Chinese cohort.
    Yang T; Zhang J; Lu JH; Yang LQ; Yang GS; Wu MC; Yu WF
    J Cancer Res Clin Oncol; 2011 May; 137(5):739-50. PubMed ID: 20607551
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of hepatocellular carcinoma in a tertiary Romanian center. Deviations from BCLC recommendations and influence on survival rate.
    Radu P; Groza I; Iancu C; Al Hajjar N; Andreica V; Sparchez Z
    J Gastrointestin Liver Dis; 2013 Sep; 22(3):291-7. PubMed ID: 24078986
    [TBL] [Abstract][Full Text] [Related]  

  • 49. NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization.
    Adhoute X; Pénaranda G; Raoul JL; Bollon E; Pol B; Letreut YP; Perrier H; Bayle O; Monnet O; Beaurain P; Muller C; Hardwigsen J; Lefolgoc G; Castellani P; Bronowicki JP; Bourlière M
    Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):706-715. PubMed ID: 28195873
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Survival benefit of hepatic resection for hepatocellular carcinoma beyond the Barcelona Clinic Liver Cancer classification.
    Furukawa K; Shiba H; Horiuchi T; Shirai Y; Haruki K; Fujiwara Y; Sakamoto T; Gocho T; Yanaga K
    J Hepatobiliary Pancreat Sci; 2017 Apr; 24(4):199-205. PubMed ID: 28160422
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of seven prognostic staging systems in patients who undergo hepatectomy for hepatocellular carcinoma.
    Kondo K; Chijiiwa K; Nagano M; Hiyoshi M; Kai M; Maehara N; Ohuchida J; Nakao H; Ohkuwa Y
    Hepatogastroenterology; 2007; 54(77):1534-8. PubMed ID: 17708292
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognosis After Resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B Hepatocellular Carcinoma: A Comprehensive Assessment of the Current BCLC Classification.
    Tsilimigras DI; Bagante F; Sahara K; Moris D; Hyer JM; Wu L; Ratti F; Marques HP; Soubrane O; Paredes AZ; Lam V; Poultsides GA; Popescu I; Alexandrescu S; Martel G; Workneh A; Guglielmi A; Hugh T; Aldrighetti L; Endo I; Pawlik TM
    Ann Surg Oncol; 2019 Oct; 26(11):3693-3700. PubMed ID: 31267302
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients.
    Leung TW; Tang AM; Zee B; Lau WY; Lai PB; Leung KL; Lau JT; Yu SC; Johnson PJ
    Cancer; 2002 Mar; 94(6):1760-9. PubMed ID: 11920539
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognosis of hepatocellular carcinoma in anti-HCV positive cirrhotic patients: a single-centre comparison amongst four different staging systems.
    Giannini E; Risso D; Botta F; Romagnoli P; Malfatti F; Fumagalli A; Testa E; Podestà E; Chiarbonello B; Polegato S; Testa R
    J Intern Med; 2004 Mar; 255(3):399-408. PubMed ID: 14871465
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Primary liver resection for patients with cirrhosis and hepatocellular carcinoma: the role of surgery in BCLC early (A) and intermediate stages (B).
    Bell R; Pandanaboyana S; Lodge JPA; Prasad KR; Jones R; Hidalgo E
    Langenbecks Arch Surg; 2017 Jun; 402(4):575-583. PubMed ID: 27456677
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hong Kong Liver Cancer Staging System Is Associated With Better Performance for Hepatocellular Carcinoma: Special Emphasis on Viral Etiology.
    Liu PH; Hsu CY; Lee YH; Su CW; Hsia CY; Huang YH; Chiou YY; Lin HC; Huo TI
    Medicine (Baltimore); 2015 Oct; 94(41):e1772. PubMed ID: 26469917
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection.
    Feng J; Zhu R; Chang C; Yu L; Cao F; Zhu G; Chen F; Xia H; Lv F; Zhang S; Sun L
    PLoS One; 2016; 11(3):e0151501. PubMed ID: 26977595
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Artificial neural networking model for the prediction of post-hepatectomy survival of patients with early hepatocellular carcinoma.
    Qiao G; Li J; Huang A; Yan Z; Lau WY; Shen F
    J Gastroenterol Hepatol; 2014 Dec; 29(12):2014-20. PubMed ID: 24989634
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A modified staging of early and intermediate hepatocellular carcinoma based on single tumour >7 cm and multiple tumours beyond up-to-seven criteria.
    Wang YY; Zhong JH; Xu HF; Xu G; Wang LJ; Xu D; Wang HW; Wang K; Xiang BD; Mao YL; Li LQ; Xing BC
    Aliment Pharmacol Ther; 2019 Jan; 49(2):202-210. PubMed ID: 30506713
    [TBL] [Abstract][Full Text] [Related]  

  • 60. LCSGJ-T classification, 6th or 5th edition TNM staging did not independently predict the long-term prognosis of HBV-related hepatocellular carcinoma after radical hepatectomy.
    Zhou L; Rui JA; Wang SB; Chen SG; Qu Q
    J Surg Res; 2010 Mar; 159(1):538-44. PubMed ID: 19111323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.